In substance use disorders, which treatment modality supports withdrawal and relapse prevention?

• A. Medication-assisted therapy (e.g., methadone, buprenorphine) plus counseling and support groups
• B. Detoxification alone
• C. No pharmacologic therapy
• D. Surgical intervention

Answer: (A)

Managing substance use disorders effectively requires addressing both withdrawal symptoms and the long-term risk of relapse. Medication-assisted therapy provides this dual approach by using medicines such as methadone or buprenorphine to blunt withdrawal and cravings, creating a stable biological foundation for recovery. When these medications are paired with counseling and support groups, patients gain coping skills, strategies to handle triggers, and ongoing social support, which together improve treatment retention and reduce relapse.

Methadone acts as a full opioid agonist, replacing the addictive opioid and preventing withdrawal symptoms, while buprenorphine is a partial agonist with a ceiling effect that lowers overdose risk. Both are most effective within a structured program that includes psychosocial care.

Detoxification alone can remove the drug from the body, but without ongoing pharmacologic management and behavioral support, relapse rates remain high because withdrawal relief is not enough to sustain long-term abstinence. No pharmacologic therapy leaves withdrawal and cravings unaddressed and tends to yield poorer outcomes. Surgical intervention is not a standard treatment for substance use disorders and does not address the ongoing biological and behavioral aspects of addiction.